What Drives Wall Street's Interest in Microsoft and AbbVie Stocks

Two stocks attract Wall Street's focus as Microsoft falls by up to 23% and AbbVie is considered a major buy opportunity. Reasons for Microsoft's drop and potential upswing are tied to upcoming events, while AbbVie garners investment due to expert recommendations.

Microsoft's stock has declined as much as 23% from its recent highs, but analysts point to a potential inflection after April 29 — the date of its Q2 FY2026 earnings announcement — as the key catalyst for a re-rating. The pullback in MSFT shares has been attributed to a combination of elevated AI infrastructure spending (capex guidance that squeezed near-term free cash flow expectations) and broader tech sector derisking amid macroeconomic uncertainty. Bulls argue the drop has created an attractive entry point in one of the highest-quality AI infrastructure franchises globally.

On the other side of the market attention, ABBV has emerged as a consensus Wall Street buy recommendation, with multiple institutional analysts citing its diversified pharmaceutical pipeline as a hedge against sector volatility. AbbVie's SKYRIZI and RINVOQ immunology franchise has been successfully filling the revenue gap left by Humira biosimilar competition, and the company's neuroscience and oncology pipeline provides additional optionality heading into 2026.

The pairing of these two names reflects a broader market dynamic: investors are simultaneously seeking AI growth exposure (Microsoft) and defensive yield with pipeline optionality (AbbVie) as volatility from geopolitical and monetary policy uncertainty remains elevated. Both stocks appear in multiple fund manager "high conviction" lists for the second half of 2026, though the Microsoft thesis depends heavily on whether April 29 earnings can demonstrate that heavy AI capex is translating into measurable revenue acceleration.